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  الةـــخص الرسـمل
      علي أحمد قايد الشاھري:ــــــمـالاســــــــ
  nidirepip)enelyhtemlyraib(-1-lyra-4 من مشتقات ةجديد ةسلسلإصطناع  :الرسالة عنوان
 313-VLS.لمادة  والتي تشابه تركيبياً 
 
    كيمياء :ــصــالتخصــــ
     ھـ٣٣٤١ يوليو :رجــالتخ تاريخ
 
 
  من مشتقات  ةجديد ةتم تحضير سلسل senidirepip)enelyhtemlyraib(-1-lyra-4
  ةلماد ا ً والتي تشابه تركيبي 313-VLS.
ماياورا بين بورونات الفنيال الحلقية المشتقة من تراي فلايت الفنايل - سوزوكيبواسطة تفاعل 
تم تفاعل الاخير  اريل البايبريدين-٤لرباعي ھايدروالبيريدين مع ھاليدات الاريل والذي انتج مادة 
  صطناع المركبات الجديدة المذكورة في الرسالةمع الديھايد ثنائي الاريل المناسب لإ 
 
 
  العلومماجستير 
  جامعـــة الملك فھــــد للبترول والمعـــادن
 المملكة العربية السعودية –الظھران 
  م٢١٠٢ يوليو
 1 
 
 
CHAPTER 1  
INTRODUCTION AND LITERATURE REVIEW 
1.1. INTRODUCTION 
 Schizophrenia is a lifelong, chronic, complex neuropsychiatric illness, afflicting 
approximately 1.5% of the world population irrespective of ethnic, economical, or 
cultural bound [1,2]. There are no specific focal characteristics for the diagnosis of 
schizophrenia, and no single symptom is consistently present in all patients. 
Consequently, its diagnosis as a single disorder, or as a variety of different disorders, is 
still debated [3].  Symptoms typically arise in early adulthood and lead to severe social 
and occupational dysfunction In general, schizophrenia involves alterations in cognitive 
and emotional functioning and the symptoms can be grouped as positive, negative and 
cognitive dysfunction. Positive symptoms include altered behavior, such as delusion, 
irrational fears, hallucinations, disorganized thoughts, extreme emotions, excited motor 
activity and incoherent speech. Negative symptoms are described as a lack of behavior, 
such as poverty of speech, social withdrawal, avolition, anhedonia and affective 
blunting, and are resistance to typical antipsychotics. Cognitive deficits include 
reduction in working memory, attention, and verbal fluency [4-6]. Depression is also a 
common feature of the condition [7]. In many patients the illness involves repeated 
relapses of acute psychotic episodes interspersed with stable phases of complete or 
partial remission. 
 Investigation into the neurobiological basis of schizophrenia has spanned over a 
century, and although definitive pathology remains elusive, certain deviations in 
neuroanatomy and neurochemistry are now reasonably well established. At the 
neuroanatomical level, there is a general enlargement of the lateral ventricles and a small 
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reduction in brain volume [8], which appears to be of neurodevelopmental (as opposed to 
neurodegenerative) origin [9].  Neuropath logical studies have provided evidence for 
subtle cytoarchitectural anomalies in areas such as the hippocampus and prefrontal 
cortex, where volume reductions are pronounced [10]. There is now also evidence for 
alterations in sub-cortical dopamine activity during the acute psychotic phases of the 
disorder [11], consistent with the proven efficacy of antipsychotics, which act on 
dopamine receptors, in the treatment of positive symptoms. However, it is likely that the 
phenotypic heterogeneity of schizophrenia at least partly reflects heterogeneity in the 
underlying pathological mechanisms, which are at present largely unknown. Recent 
developments in molecular genetics have paved the way for significant advances in our 
mechanistic understanding of schizophrenia and the extent to which these mechanisms 
are shared with other neuropsychiatric disorders.  
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1.2. LITERATURE REVIEW 
 Since the discovery antipsychotic agent chlorpromazine 1more than 50 years ago 
[12], the number of antipsychotic agents for the treatment of schizophrenia has 
tremendously increased. The development of the first-generation antipsychotics, or 
typical antipsychotics, had for the first time made possible to treat the ‘positive’ 
symptoms such as delusions and hallucinations of schizophrenia, leading to the 
deinstitutionalization of the world's mentally ill. The typical antipsychotic drugs, 
however, are generally not effective at treating the ‘negative’ symptoms, for instance 
anhedoniaand lack of motivation; and cognitive dysfunction of schizophrenia and have a 
high liability of extrapyramidal side effects (EPS) [13].Atypical antipsychotic drugs are 
different from typical antipsychotic drugs by virtue of a relative lack of EPS and serum 
prolactin elevation as compared with typical antipsychotic drugs. Clozapine 2itself has 
become the ‘gold standard’ antipsychotic medication because of its absence of 
debilitating extrapyramidal side effects and its demonstrated clinical superiority in 
treatment-resistant schizophrenia [14] and suicidality. The beneficial effect on negative 
symptoms and cognition ofclozapine2 is unclear [13, 15].Clozapine2, however, is 
associated with serious side effects including weight gain, diabetes and an increased risk 
of seizures and agranulocytosis [16].The proven superiority of clozapine 2 [17, 18] over 
other antipsychotic drugs has led to an intense effort over the past 15–20 years to 
develop clozapine-like atypical antipsychotics that are safer and better tolerated than 
clozapine2. Thus multiple atypical and pseudo-atypical antipsychotic drugs, 
includingrisperidone3, olanzapine4, quetiapine5 and ziprasidone6have been discovered. 
Expectations from these drugs to treat negative symptoms and cognition were initially 
high[19] which were, however, have not been realized[20].While most of the new drugs 
offer, at best, modest advantages over the typical antipsychotic drugs with regard to 
improvement in negative symptoms, cognitive impairment and functional capacity, the 
improvements are not consistent among studies[21-23]. In addition, the atypical 
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antipsychotics have substantial side-effect liability, specifically weight gain and the 
metabolic syndrome [24, 25]. Even though the introduction of antipsychotic medications 
has had a profound effect on the treatment of schizophrenia over the past 50 years, and 
the atypical antipsychotic drugs have provided a larger and more diverse armamentarium 
of treatment options, the advances and improvements that have been made since the 
discovery of the antipsychotic properties of chlorpromazine1have been small and 
incremental. Thus, enormous challenges remain in the long-term treatment of this 
debilitating disease and continuing with the current paradigms of drug discovery is 
unlikely to produce significant advances [26, 27]. It is therefore important to continue to 
pursue diverse molecular targets for discovering new antipsychotic compounds and to 
devise novel paradigms for drug discovery in schizophrenia. 
 The main obstacle to the discovery and development of novel treatments for 
schizophrenia stems from poor understanding of the biological processes involved in 
schizophrenia and is not sufficient to predict the therapeutic value of novel drug targets 
[27]. Thus, unvalidated targets are frequently left unpursued by the pharmaceutical 
industry and, frequently, companies have focused on alterations of existing medications 
(that is, separating enantiomers or marketing active metabolites; for example 9-OH-
risperidoneor paliperidone 7 [28], finding additional compounds that hit known and 
validated targets [29]. These methods, however, cannot continue indefinitely as the 
number of such possibilities is limited and thus it is critical to find new approaches to 
drug development. Interestingly, many of the atypical will soon be going off patent, 
beginning with the launch of generic risperidone3in 2007. Thus, there is significant 
interest and urgency within the pharmaceutical industry and among schizophrenia basic 
scientists and clinicians in developing safer and more-effective treatments for 
schizophrenia. 
 While we await potential therapeutic avenues arising from improved 
understanding of schizophrenia susceptibility mechanisms, several novel 
pharmacological strategies, based largely on prior neurochemical hypotheses of 
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schizophrenia, have recently shown promise in clinical trials. The path physiology of 
this complex and uniquely human disorder is believed to be associated with 
dopaminergic hyperactivity in the mesolimbic system of the brain [30]. The introduction 
of dopamine receptor blockers such as haloperidol 8 have been treatment of choice for 
decades [31]. The second-generation atypical drug, emerged after almost three decades, 
cause no or minimal EPS at therapeutically relevant doses due to multi receptor affinity 
profile. For most atypical drugs (e.g., clozapine 2, risperidone 3, olanzapine 4 and 
ziprasidone 6 antagonisms at D2 receptors is accompanied by 5-HT2A receptors 
blockades. The ratio of 5-HT2/D2 rather than the absolute affinity for D2 and 5-HT2 
receptors may be important for defining an atypical antipsychotic profile of these agents 
[32]. They are claimed to be active against both positive and negative symptoms, even 
though their superiority on negative symptoms compared with that of typical 
antipsychotics is by no means firmly established [33]. Except for clozapine 2 in treatment-
resistant schizophrenia, comparative studies have not shown efficacy advantage for any 
one of these agents, and treatment discontinuation rates are very high [34].Moreover, 
because of their significant affinity for numerous other receptors, they do exhibit a 
variety of other side effects[35,36]. These include weight gain (5HT2C receptor blockade), 
postural hypotension, sedation and dizziness (α1 adrenoceptor blockade), dry mouth 
(muscarinic M1 receptor blockade), and sedation (histamine H1 receptor blockade). 
 Newer atypical agents (e.g., Aripiprazole 9, bifeprunox 10, and SSR-181507 11 
differ in that they act as partial agonist at D2 receptors, although also interact with array 
of other CNS targets. Such therapeutic strategy features the stabilization of dopamine 
function, instead of the inhibition of the D2 transmission caused by previous 
antipsychotic drugs [37], either by post-synaptic dopamine D2 receptor antagonism [38] 
and/or partial agonism [39] at presynaptic dopamine D2 receptors. 
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1.3. SCHIZOPHRENIA IN SAUDI ARABIA 
Schizophrenia in Saudi Arabia is traced back to the early reports in 1975 when sixty-
nine schizophrenic patients of both sexes, were investigated for the phenomenology and 
frequency of visual hallucinations in Taif [40]. The following report was related to 
discover the incidence of Schneider's first-rand symptoms and their usefulness in 
diagnosing schizophrenia in Saudi Arabia [41, 42]. Further studies have not only 
demonstrated that the course of chronic schizophrenia in Saudi families had developed 
symptoms of delusion of pregnancy[43]but also that out of total of 1366 psychiatric 
patients in 10 years from different parts of the Eastern Province of the Kingdom of Saudi 
Arabia, 19.5% had schizophrenia[44]. The other literature reports on schizophrenia in 
Saudi Arabia dealt in: the comparison of the life-event histories of the schizophrenic 
patients [45], a familial tendency towards schizophrenia [46] a cross-cultural comparison 
studies between British and Saudi Arabian patients [47, 48] and quality of life of patients of 
schizophrenia [49]. The previous studies in the Kingdom have not addressed the core 
issue of treatment and remedies to the illness so far. We aim to synthesize novel, 
potential antipsychotic compounds to develop more effective and less toxic therapies for 
schizophrenia. To the best of our knowledge, this will be the first study of its nature in 
the Kingdom that would aim to discover the treatment and relieve to the symptoms of 
illness. 
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CHAPTER 2  
RESULTS AND DISCUSSION 
2.1.  SYNTHESIS OF ALDEHYDES (B-F) AND BORONIC ESTER (30) 
 
 In order to accomplish the synthesis of the desired final compounds (10a-10f, 11a-
11f,12a-12f), access to aldehydes (a-f) and boronic ester 30 was imperative. 
Intermediate (a) was commercially available whereas (b) was synthesized by Suzuki 
reaction of aldehyde 13with boronic acid 14 in a mixture of toluene and ethanol, using 
Pd(PPh3)4 as catalyst and sodium carbonate as base. To access intermediates (c) and (d), 
aldehyde 15 was first converted to bromoaldehyde 16 by the action of bromine in acetic 
acid [51], followed by the Suzuki reaction of the latter with boronic acids 17 and 18, 
under identical reaction conditions as described for intermediate (b), to produce 
intermediates (c) and (d), respectively[51-54] (Scheme 1).The synthesis of the intermediate 
(e) was started with protection of aldehyde 19 to get acetal 20. Bromine lithium 
exchange of 20 was ensued by treating it with n-butyllithium at lower temperature, 
followed by quenching the resultant lithiate with cyclopentanone afforded alcohol 21. 
Acid exposure of the latter under heating furnished the desired intermediate 
(e)[55](Scheme 2). Likewise the synthesis of the desired intermediate (f) was commenced 
from the Grignard reaction of ester 22with alkylmagnesium bromide, originated from 
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the reaction of 1, 4-dibrmoethane with magnesium in refluxing THF, to produce alcohol 
23. The dehydration of the latter with HCl in toluene produced intermediate 24 in a 
moderate yield. Bromine-lithium exchange of intermediate 24by treating it with n-
butyllithium at lower temperature, followed by quenching it with N-formylmorpholine 
yielded the desired (f) in a low yield (7%)  [56] (Scheme 3).  
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Scheme 1: Synthesis of intermediate (b-d) 
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Scheme 2: Synthesis of intermediate (e) 
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Scheme 3: Synthesis of intermediate (f) 
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 In order to improve the synthesis of (f), a modified procedure was adopted as 
depicted in Scheme: 4. Conversion of aldehyde 16 to its corresponding acetal 25 was 
accomplished with the aid of trimethylorthoformate and catalytic amount of PPTS. 
Bromine-lithium exchange of 25, followed by trapping the resultant aryllithium with 
cyclopentanone gave alcohol 26, which was subsequently exposed to acid in acetonitrile 
to generate the desired intermediate (f) (Scheme 4). 
N
16
CHOBr
N
25
CBr
OMe
OMe
N
C
OMe
OMeOHBuLi, THF, - 78 o
O
HCl, CH3CN, heat
N
OHC
(f)
26
MeOH, PPTS
CH(OCH3)3
H H
 
Scheme 4 : Synthesis of intermediate (f) 
 Having secured the synthesis of aldehydes b-f, we next moved on towards the 
synthesis of boronic ester [54] 30 as outlined in Scheme: 5. Reaction of lithium enolate, 
derived from reaction of boc-pyridone 27 with LiHMDS at lower temperature, with N-
phenylbis(trifluoromethanesulfonimide) generated triflate 28. Reaction of triflate 28 
with bis(pinacolato)diboron under Suzuki reaction conditions produced the desired 
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boronic ester 30. The purifications of both 28 and 30 were proved to be quite tedious and 
required the use of basic alumina (Scheme 5).  
30
2827
N
O
Boc
N
OTf
Boc N
B
Boc
OO1) LiHMDS, THF, - 78 oC
2) PhNTf2, - 78 to 0 oC
B
O
O
B
O
O
PdCl2dppf, dppf, KOAc, dioxane
29
 
Scheme 5 : Synthesis of intermediate (30) 
2.2. SYNTHESIS OF INTERMEDIATES (10-12) 
 Having accomplished the synthesis of the desired aldehydes (b-f) and boronic 
ester (30), we next focused on the synthesis of intermediates 10-12. Access to 
intermediate 10 required the synthesis of intermediate 36, which in turn was synthesized 
as outlined in Scheme: 7. Acylation of bromoaniline 31 with cinnamoyl chloride 32 
generated the amide 33. Acid catalyzed cyclization of the latter in chlorobenzene at 
higher temperature rendered the intermediate 34, which was exposed to phosphorous 
oxychloride to produce quinoline 35.Condensation of the latter withsodium methoxide 
yielded the desired 36 (Scheme 6).          
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AlCl3, 125 oC, 2 h
(48%)
POCl3
125 oC, 2 h
(80%)
35
NaOCH3, CH3OH
reflux, 5 h
(91%)
36
 
Scheme 6 : Synthesis of intermediate (36) 
 The synthesis of intermediate 36 eventually allowed us to march towards the 
synthesis of arylpiperidine 10. Suzuki-Miyaura reaction of cyclic vinyl boronates 30 
with bromoquinoline 36 [55].generated compound 37, which in turn was hydrogenated at 
50 psi for 6 h to furnish intermediate 38. Exposure of the latter to trifluoroacetic acid at 
room temperature smoothly produced the desired intermediate 10 in an overall yield of 
43% from 36 (Scheme 7). 
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Scheme 7 : Synthesis of intermediate (10) 
 Owing to the difficulty in purifications of 28 and 30, the synthesis of 
arylpiperidines 11 and 12 were initiated through a different synthetic approach. The 
quinoline 35 was condensed with sodium phenylmethanolate, generated by the action of 
benzyl alcohol and sodium hydride in DMF, to produce quinoline 39.Lithiation of 
intermediate 39 in THF at -78 oC followed by quenching it with N-protected 
piperidinone gave alcohol 40 in 68% yield. The dehydration of latter was ensued by 
refluxing it in conc. HCl and MeOH to generate compound 41 in a moderate yield 
(56%). To produce the desired intermediate 11 from compound 41, removal of N-
protection and reduction of the double bond were required. Hence compound 41 was 
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subjected to hydrogenation in a Parr apparatus at 60 psi for 5 hours. The benzyl 
deprotection, however, proved to be stubborn and the reaction yielded very polar 
mixture of products which were difficult to separate (Scheme 8). 
N
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OBn
1) BuLi, THF, -78 o
2) NO Bn
(68 %)
N OBn
N
Bn
HO
HCl, MeOH
reflux, 5 h
N
H
O
N
Bn
H2, Pd-C N
H
O
N
N
H
O
N
39
41 11 12
(56 %)
40
H H
N Cl
Br
35
BnONa, DMF
heat, 5 h
(86 %)
 
Scheme 8 : Synthesis of arylpiperidines (11) and (12) 
 Thus the desired intermediates 11 and 12 were synthesized from an alternative 
route as outlined in Scheme 10. Suzuki-Miyaura reaction of cyclic vinyl boronates 30 
[57].with bromoquinoline 39 generated compound 42. Hydrogenation of intermediate 42 
in a Parr apparatus at 50 psi for 6 hours followed by column chromatographic 
purifications on silica gel produced intermediates 43 and 44 in 3:7 ratio. Exposure of 
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compounds 43 and 44 to trifluoroacetic acid at room temperature smoothly furnished the 
desired intermediates 11 and 12 in high yields (Scheme 9). 
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Scheme 9 : Synthesis of arylpiperidines 11 and 12 (an alternate route). 
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 Having the desired arylpiperidines (10-12) and biarylaldehdyes (b-f) in hands, 
we next performed the reductive amination of arylpiperidines and aldehydes in 1,2-
dichloroethane, using NaBH(OAc)3as reducing agent to accomplish the final 
ligands(10a-10f)(Schemes: 10, 11and 12). In the similar fashion compounds 11a-11f 
and 12a-12fwere synthesized from the reductive amination of the arylpiperidines 11 and 
12 with the corresponding aldehydes a-f. 
N
N
H CF3COO
OCH3
10
CHO
DCE, Et3N, NaBH(OAc)3
0 oC - rt, 4 h
(70%)
N
N
OCH3
X
X = H (a)
X = F (b)
X
X = H (10a)
X = F (10b)
 
Scheme 10 : Synthesis of 1-aryl-4-(biarylmethylene) piperidines 10a&10b 
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N
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H
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Scheme 11 : Synthesis of 1-aryl-4-(biarylmethylene) piperidines 10c& 10d 
 20 
 
 
N
N
H CF3COO
OCH3
10
DCE, Et3N, NaBH(OAc)3
0 oC - rt, 4 h
(70%)
N
N
OCH3
X = C (10e)
X = N (10f)
X
H
O
X = C (e)
X = N (f)
X
 
Scheme 12 : Synthesis of 1-aryl-4-(biarylmethylene) piperidines 10e& 10f 
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CHAPTER 3  
EXPERIMENTAL WORK 
3.1. INSTRUMENTATION AND CHEMICALS 
 
 1H NMR and 13C NMR spectra were recorded on JEOL Lambda 500 and 400 MHz 
spectrometer. Chemical shifts were reported in ppm (δ) relative to tetramethyl silane 
(TMS) by using (CDCl3), (DMSO) or methanol as deuterated solvents. Multiplicities 
were reported as singlet (s), doublet (d), triplet (t), quartet (q) or multiplet (m), and 
coupling constants (J) were reported in hertz (Hz). IR Spectra were recorded on a 
NicoletTM 6700 FT-IR spectrometer from a thermo-electron by using a smart orbit for 
net samples, and they were reported in wave numbers (cm-1) (Spectral resolution, 4 cm-1; 
Number of scans, 4). Mass was determined by using Agilent 7000A Triple Quadrupole 
GC/MS.  
     Elemental analysis was carried out on a EuroVector Elemental Analyzer Model 
EA3000. All mps are uncorrected. Thin layer chromatography (TLC) was frequently 
used to monitor reactions and to give qualitative determination of sample purity. TLC 
analyses were performed on silica gel Merck 60 F254 plates, and spots were visualized 
under a spectroline UV lamp operating at short and long wavelength ranges. 
Visualization was improved by dipping plates into a phosphomolybdic acid solution, and 
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then by drying in a blast of hot air. Purification of the products was carried out either by 
recrystallization or by flash column chromatography. The column was packed with silica 
gel 100 from Fluka Chemie AG (Buchs, Switzerland). Ethyl acetate, petroleum ether 
(boiling fraction 60-80) and hexane were used as eluting solvents, in volume-by-volume 
ratios as stated.       
     Chemicals were purchased from commercial sources, and they were used without any 
further purification unless otherwise specified. All solvents were of reagent grade, and 
dichloromethane was passed through alumina before use. Specially dried 53 (anhydrous) 
solvents were used where necessary. Glassware for moisture-sensitive reactions were 
oven dried at 120-140 °C for at least three hours and cooled in a desiccators prior to use. 
Some of the reactions were run in an inert atmosphere of nitrogen as stated. 
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3.2. SYNTHESIS OF NEW 4-ARYL-1-(BIARYLMETHYLENE) PIPERIDINES 
 
3.2.1. Synthesis of compound 4'-fluorobiphenyl-4-carbaldehyde (b) 
 4-bromobenzaldehyde (2.76 g, 14.92 mmol) was dissolved in toluene (100 mL), 
an aqueous 2.0 M Na2CO3 solution (47 mL) and an ethanolic solution (47 mL) of the 
corresponding boronic acid (2.5 g, 17.86 mmol) were added. The mixture was 
deoxygenated under reduced pressure and flushed with nitrogen. After repeating this 
cycle several times Pd(PPh3)4 (4 mol%) was added and the resulting suspension was 
heated under reflux for 8 h. After cooling ethyl acetate (20 mL) and water (20 mL) were 
added and the organic phase was separated. The water phase was extracted with ethyl 
acetate (2 x 20 mL). The combined organic phases were washed with brine, dried over 
Na2SO4, filtered over a short plug of celite and evaporated under reduced pressure. The 
compounds were purified by flash chromatography on silica gel, eluting with 
CH2Cl2:hexanes (8:2) to obtained the title compound as a light yellow solid (2.88 g, 
95%). 1H NMR (CDCl3, 500 MHz)  7.18-7.14 (m, 2H), 7.61-7.58 (m, 2H), 7.71-7.69 
(m, 2H), 7.95-7.93 (m, 2H), 10.05 (s, 1H, CHO). 13C NMR (125.7 MHz, CDCl3) δ: 
116.08, 116.25, 127.74, 129.25, 129.31, 130.54, 135.44, 146.42, 162.53, 164.52, 192.36.  
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3.2.2. Synthesis of compound 5-bromonicotinaldehyde (16) 
 A 1-l three-neck flask was charged with glacial acetic acid (300 ml) and 3-
pyridinecarboxaldehyde (30 g, 0.278 mmol). To this solution, bromine (90 g, 0.5 mmol) 
was added dropwise over 30 min at room temperature. The reaction mixture was heated 
under reflux for 2 h while fumes of HBr were exhausted. The mixture was cooled, 
poured into 600 ml of H2O, and extracted 3 times with 200 ml each of CH2Cl2. The 
combined organic layers were washed with brine, and then with 2N NaOH, before being 
dried over MgSO4. Removal of the solvent produced a dark brown product which was 
purified by column chromatography on a silica gel column, eluted first with CH2Cl2, 
then with CH2Cl2:EtOAc (9:1) to give 5-bromo-3-pyridinecarboxaldehyde (14.8 g, 28%) 
as light yellow crystals, mp 95–96 oC. 1H NMR (CDCl3, 500 MHz)  8.29–8.33 (m, 
1H), 8.92 (d, 1H, J = 2.6 Hz), 8.99 (d, 1H, J = 1.94 Hz), 10.10 (s, 1H). 
3.2.3. Synthesis of compound (c) and (d) 
 According to the procedures of compound (b), the suzuki coupling of 16 with 
phenyl boronic acid and 4-fluorophenyl boronic acid produced the desired (c) (82%) and 
(d) (86%). 
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Compound5-phenylnicotinaldehyde (c):  
 Light yellow thick oil, 82% yield. 1H NMR (CDCl3, 500 MHz)  7.30 (m, 1H), 
7.47-7.43 (m, 2H), 7.60 (d, 2H, J = 8.0 Hz), 9.05 (d, 2H, J = 2.6 Hz), 10.18 (s, 1H). 13C 
NMR (125.7 MHz, CDCl3) δ: 127.28, 128.98, 129.44, 131.48, 133.78, 136.38, 137.38, 
150.86, 153.41, 191.23. 
Compound5-(4-fluorophenyl) nicotinaldehyde (d): 
 Light yellow solid, 86% yield.1H NMR (CDCl3, 500 MHz)  7.18-7.23 (m, 2H), 
7.55-7.62 (m, 2H), 8.31 (s, 1H), 9.05 (s, 2H), 10.20 (s, 1H). 13C NMR (125.7 MHz, 
CDCl3) δ: 115.90, 129.24, 131.48, 136.65, 137.38, 151.01, 153.32, 191.19. 
3.2.4. Synthesis of compound 2-(3-bromophenyl)-1, 3-dioxolane (20) 
 3-bromobenzaldehyde (19, 27.9 g, 151 mmol) and ethylene glycol (13.8 g, 222 
mmol) were dissolved in 120 mL of benzene. After the addition of 45 mg of 4-
toluenesulfonic acid, the mixture was refluxed in a Dean-Stark apparatus until no more 
water was produced. The reaction mixture was washed with NaHCO3 solution, and the 
organic layer was then separated and dried over anhydrous Na2SO4. After the 
evaporation of benzene and distillation under vacuum, 2-(3-bromophenyl)-1,3-dioxolane 
was obtained as a colorless liquid. Yield: 25 g, 72%. 1H NMR (400 MHz, CDCl3) 
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7.64 (t, 1H, 2-H), 7.49 (m, 1H, 6-H), 7.40 (m, 1H, 4-H), 7.26 (t, 1H, 5-H), 5.77 (s, 1H, 
CH(OCH2)2), 4.14-3.99 (m, 4H, CH(OCH2)2.  
3.2.5. Synthesis of compound 1-(3-(1, 3-dioxolan-2-yl) phenyl) 
cyclopentanol (21) 
 n-Butyllithium (2.5M in THF, 10 mL, 25 mmol) is slowly added to a flask 
containing THF (60 mL) at -78 oC, followed by the dropwise addition of compound  20 
(5.20 g, 22.72 mmol) in dry THF (20 mL). After being stirred the mixture for 0.5 h at -
78 oC, a solution of cyclopentanone (3 mL, 34 mmol) was added dropwise. The 
temperature of the reaction was allowed to come back up to ambient temperature over 
two hours. The solution is treated with H2O (15 mL), diluted with EtOAc (100 mL) and 
washed with water and finally with brine. The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. Column chromatography over silica eluting with 
EtOAc:hexanes (4:6) and then changing to (7:3) afforded the product as light yellow 
thick oil (3.38 g, 65%). 1H NMR (400 MHz, CDCl3) 1.61 (s, 1H), 1.86 (m, 2H), 1.99 
(m, 6H), 4.04 (m, 2H), 4.13 (m, 2H), 5.81 (s, 1H), 7.36 (m, 2H), 7.49 (m, 1H), 7.61 (m, 
1H). 
 27 
 
 
3.2.6. Synthesis of compound 3-cyclopentenylbenzaldehyde (e) from 
(21) 
 To a solution of compound 21 (3 g, 12.82 mmol) in acetonitrile (50 mL) at 0 oC 
was added 6M HCl (15 mL) and the reaction mixture was heated to 80 oC for 12 hours. 
The mixture was cooled to room temperature, neutralized with saturated Na2CO3 and 
concentrated under reduced pressure to evaporate acetonitrile. The residue were taken in 
EtOAc (100 mL) and washed with water, brine, dried over Na2SO4 and evaporated. 
Column chromatography over silica eluting with EtOAc:hexanes (3:7) afforded the 
product as a light yellow thick oil (1.24 g, 56%). 1H NMR (400 MHz, CDCl3) 2.06 
(m, 2H), 2.57 (m, 2H), 2.72 (m, 2H), 6.30 (s, 1H), 7.49 (t, 1H), 7.71 (m, 2H), 7.61 (m, 
1H), 7.91 (s, 1H0, 10.02 (s, 1H). 
3.2.7. Synthesis of compound 1-(5-bromopyridin-3-yl) cyclopentanol 
(23) 
 To a suspension of 2.25 g of magnesium (92.6 mmol) in THF (25 mL) was added 
a crystal of iodine and a few drops of 1,4-dibromobutane. The mixture was heated at 65 
°C until it turned colorless, then a solution of 1,4-dibromobutane (10 g, 46.3 mmol) in 
THF (50 mL) was added dropwise while maintaining the reaction at 65 °C. The reaction 
mixture was then stirred at this temperature for 4 hours and cooled to 0 °C. A solution of 
ethyl 5-bromo-3-pyridinecarboxylate (22, 10 g, 46.3 mmol) in 60 mL of THF was added 
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dropwise. The mixture was slowly brought to room and stirred for 16 hours. The 
reaction was poured in a cold, saturated aqueous solution of ammonium chloride and 
extracted with ethyl acetate. The combined organic layer was washed with water, brine 
dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash 
column chromatography (silica gel, cyclohexane-ethyl acetate, 70:30) to give 2.70 g 
(24%) of the product as a white solid. 1H NMR (400 MHz, CDCl3)  1.74-1.77 (m, 2H), 
1.85-1.88 (m, 6H), 2.70-2.73 (m, 2H), 3.93 (s, 1H), 7.15 (d, J = 5.0 Hz, 1H), 8.38 (d, J = 
5.0 Hz, 1H), 8.64 (s, 1H). 
3.2.8. Synthesis of compound 3-bromo-5-cyclopentenylpyridine (24) 
 A solution of 1-(5-bromo-pyridin-3-yl)-cyclopentanol 23(1.70 g, 11.3 mmol) in 50 
mL of toluene and containing 5 mL of concentrated HCl was heated at 120 °C for 12 
hours with continuous removal of the water formed. The reaction mixture was cooled to 
room temperature and poured into a saturated aqueous solution of sodium bicarbonate, 
extracted with ethyl acetate and the combined organic layer washed with water and 
brine. The organic solution was dried over sodium sulfate, filtered and the solvent 
removed in vacuo. The residue was purified by flash column chromatography (silica gel, 
cyclohexane-ethyl acetate, 60:40) to give V (1.52 g, 60%) as an off-white solid. mp = 43 
°C; 1H NMR (400 MHz, CDCl3)  2.03-2.06 (m, 2H), 2.55-2.58 (m, 2H), 2.70-2.73 (m, 
2H), 6.31 (s, 1H), 7.80-7.82 (m, 1H), 8.49 (d, J = 2.0 Hz, 1H), 8.59 (d, J = 2.0 Hz, 1H). 
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3.2.9. Synthesis of compound 5-cyclopentenylnicotinaldehyde (f) from 
(24) 
 A solution of 3-bromo-5-cyclopenten-1-yl-pyridine 24(1 g, 4.46 mmol) in 25 mL 
of diethyl ether was added to a solution of n-butyl lithium (1.6 M in hexane, 4.20 mL, 
6.68 mmol) in 25 mL of diethyl ether at -60 °C. The reaction mixture was stirred for 2 h 
at -60 °C, and then 4-morpholinecarboxaldehyde (1.40 mL, 13.38 mmol) was added. 
The reaction mixture was stirred for 1 h at -60 °C and then quenched with water, washed 
with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (silica gel, cyclohexane/ethyl 
acetate, 80:20) to afford ( f ) (0.35 g, 45%) as an off-white solid, mp = 50 °C: 1H NMR 
(400 MHz, CDCl3)  2.09-2.11 (m, 2H), 2.60-2.62 (m, 2H), 2.70-2.73 (m, 2H), 6.49 (s, 
1H), 8.32 (s, 1H), 8.89 (s, 1H), 8.93 (s, 1H), 10.10 (s, 1H). 
3.2.10. Synthesis of compound 3-bromo-5-(dimethoxymethyl) pyridine 
(25) 
 p-Toluenesulfonic acid (2.7 g, 143 mmol) and trimethyl orthoformate (1.6 mL, 
143 mmol) were added to a stirred solution of compound 16 (2.42 g, 13 mmol) in MeOH 
(50 mL). The mixture was heated at reflux for 18 hours and then cooled to room 
temperature. Aqueous Na2CO3 was added to attain pH 8 and the mixture was 
concentrated by evaporation. H2O was added and the mixture extracted with EtOAc. The 
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extract was washed with brine, dried over Na2SO4 and evaporated. Column 
chromatography over silica eluting with EtOAc:hexanes (3:7) afforded the product as a 
yellow oil (2.1 g, 70%). 1H NMR (400 MHz, CDCl3) 3.34 (s, 6H), 5.44 (s, 1H), 7.94 
(d, 1H), 8.59 (d, 1H), 8.64 (d, 1H). 
3.2.11. Synthesis of compound 1-(5-(dimethoxymethyl) pyridin-3 yl) 
cyclopentanol (26) 
 n-Butyllithium (2.5M in THF, 5 mL, 12.5 mmol) is slowly added to a flask 
containing THF (30 mL) at -78 oC, followed by the dropwise addition of compound  25 
(2.57 g, 11.4 mmol) in dry THF (10 mL). After being stirred the mixture for 0.5 h at -78 
oC, a solution of cyclopentanone (1.5 mL, 17.1 mmol) was added dropwise. The 
temperature of the reaction was allowed to come back up to ambient temperature over 
two hours. The solution is treated with H2O (10 mL), diluted with EtOAc (50 mL) and 
washed with water and finally with brine. The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. Column chromatography over silica eluting with 
EtOAc:hexanes (4:6) and then changing to (7:3) afforded the product as light yellow 
thick oil (1.68 g, 62%). 1H NMR (400 MHz, CDCl3) 1.86 (m, 2H), 2.02 (m, 6H), 3.32 
(s, 6H), 5.42 (s, 1H), 7.88 (s, 1H), 8.48 (s, 1H), 8.646 (s, 1H). 
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3.2.12. Synthesis of compound 5-cyclopentenylnicotinaldehyde (f) from 
(26) 
 To a solution of compound 26 (1.5 g, 5.33 mmol) in acetonitrile (15 mL) at 0 oC 
was added 6M HCl (5 mL) and the reaction mixture was heated to 80 oC for 12 hours. 
The mixture was cooled to room temperature, neutralized with saturated Na2CO3 and 
concentrated under reduced pressure to evaporate acetonitrile. The residue were taken in 
EtOAc (50 mL) and washed with water, brine, dried over Na2SO4 and evaporated. 
Column chromatography over silica eluting with EtOAc:hexanes (4:6) afforded the 
product as off white solid (0.60 g, 65%). 
3.2.13. Synthesis of compoundtert-butyl 4(trifluoromethylsulfonyloxy)-
5, 6-dihydropyridine-1(2H)-carboxylate (28) 
 To a stirred solution of 27 (10 g, 50.2 mmol) in dry THF (200 mL) at -78 oC was 
added 1M solution of lithium bis(trimethylsilyl) amide in THF (60.2 mL, 60.2 mmol) 
over 10 min under N2. The reaction mixture was stirred for 1 h and N-
phenyltrifluoromethanesulfonimide (21.73 g, 60.2 mmol) was added in one portion. The 
reaction mixture was allowed to warm to 0 oC and stirred for 4 h. The solvent was 
removed in vacuo and the residue was dissolved in EtOAc (200 mL), and washed 
successively with 2M NaOH, H2O and brine. Drying over Na2SO4and evaporation under 
vaccuo yielded a brown oily material. The later was chromatographed on basic alumina, 
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eluting with EtOAc:hexanes (1:9), to obtain compound 28 as light yellow oil (13.64 g, 
82%). 1H-NMR (400 MHz, CDCl3) δ: 1H NMR (400 MHz, CDCl3) 1.47 (s, 9H), 2.44 (s, 
2H), 3.63 (m, 2H), 4.04 (m, 2H), 5.72 (br. s, 1H). 
3.2.14. Synthesis of compound tert-butyl 4-(4, 4, 5, 5-tetramethyl 1, 3, 
2-dioxaborolan-2-yl)-5, 6-dihydropyridine-1(2H)carboxylate (30) 
 To a flask were added bis(pinacolato)diboron (2.92 g, 11.5 mmol), KOAc (3.1 g, 
31.4 mmol), PdCl2dppf (0.22 g, 0.31 mmol), dppf (0.17 g, 0.31 mmol) and the contents 
flushed with nitrogen. A solution of the triflate (3.44 g, 10.4 mmol) in 1,4-dioxane (60 
mL) was added and the mixture was stirred at 80°C overnight. After work-up, flash 
chromatography (SiO2, Pentane/EtOAc) gave the boronate 30 as white solids (2.32 g, 
72%). 1H NMR (400 MHz, CDCl3) 1.25 (s, 12H), 1.45 (s, 9H), 2.20 (m, 2H), 3.43 (m, 
2H), 3.95 (m, 2H), 6.45 (br. s, 1H). 
3.2.15. Synthesis of compound N-(2-bromophenyl) cinnamamide (33) 
 A mixture of cinnamoyl chloride (84 g, 0.50 mol), 2-bromoaniline (86 g, 0.50 
mol), and potassium carbonate (0.10 kg, 0.75 mol) in water (0.25 L) and acetone (0.20 
L) was kept for 2 h at 0 °C before being poured into ice-water (0.50 L). The precipitate 
formed was collected and crystallized from hexanes to afford compound 33; colorless 
prisms; m.p. 151-152 °C; yield: 133 g (88%). The spectral data coincided to the 
literature reported values[56]1H NMR (CDCl3, 500 MHz)  6.60 (d, J = 15.9 Hz, 1 H), 
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6.99 (t, J = 7.9 Hz, 1 H), 7.34 (t, J = 7.9 Hz, 1 H), 7.59-7.38 (m, 6 H), 7.77 (d, J = 15.9 
Hz, 1 H), 7.81 (s, 1 H), 8.51 (d, J = 8.2 Hz, 1 H).  
3.2.16. Synthesis of compound 8-bromoquinolin-2(1H)-one (34) 
 A solution of 2-bromocinnamanilide (0.12 kg, 0.40mol) and aluminium chloride 
(0.32 kg, 2.4 mol) in chlorobenzene (0.40 L) was heated to 125 °C for 2 h. At 50 °C, it 
was then poured onto ice, and the resulting precipitate was filtered and crystallized from 
ethanol; colorless needles; m.p. 197-198 °C; yield: 43.0 g (48%). The spectral data 
coincided to the literature reported values [56]. 1H NMR (CDCl3, 500 MHz)  6.68 (d, J 
= 9.4 Hz, 1 H), 7.80 (t, J = 7.8 Hz, 1 H), 7.53 (dd, J = 7.8, 1.1 Hz, 1 H), 7.71 (d, J = 9.4 
Hz, 1 H), 8.11 (s, 1 H). 
3.2.17. Synthesis of compound (35) 
 Phosphorus oxychloride (37 mL, 61 g, 0.40 mol) and 34 (45 g, 0.20 mol) were 
heated to 125 °C for 2 h before being poured onto ice. The resulting precipitate was 
filtered and crystallized from methanol; colorless prisms; m.p. 114-115 °C; yield: 39.33 
g (81%). The spectral data coincided to the literature reported values [56].  1H NMR 
(CDCl3, 500 MHz)  7.49-7.39 (m, 2 H), 7.78 (d, J = 7.8 Hz, 1 H), 8.05 (d, J = 7.8 Hz, 
1 H), 8.10 (d, J = 8.3 Hz, 1 H).  
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3.2.18. Synthesis of compound 8-bromo-2-methoxyquinoline (36) 
 To a solution of 35 (4.85 g, 20 mmol) in methanol (90 mL) was added NaOMe 
(2.4 g, 100 mmol) and refluxed for 5 h. The solvent was evaporated under reduced 
pressure, and ethyl acetate (150 mL) was added and washed with H2O and brine, dried 
over Na2SO4 and evaporated to obtain compound 36 as a light violet solid (4.33 g, 
91%).1H NMR (CDCl3, 500 MHz)  4.14 (m, 3 H), 6.94 (d, J = 8.8 Hz, 1 H), 7.22 (m, 1 
H), 7.68 (d, J = 8.8 Hz, 1 H), 7.95 (m, 2 H). 13C NMR (125.7 MHz, CDCl3) δ: 53.35, 
113.75, 122.51, 124.38, 126.17, 127.10, 133.11, 139.20, 143.83, 163.08.  
3.2.19. Synthesis of compound tert-Butyl 4-(2-methoxyquinolin-8-yl)-5, 
6-dihydropyridine-1(2H)-carboxylate (37) 
Following the same procedure adopted for the synthesis of 42, the title compound 
was obtained from Suzuki reaction of boronate 30 and bromoquinoline 36 as dark brown 
gum, (0.64 g, yield 42 %). M.p. 132-133 oC. – IR (neat): ν = 3037, 2978, 1677, 1604, 
1486, 1176 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.49 (s, 9H, OC(CH3)3), 2.85 (br. s, 
2 H, piperidine H), 3.70 (m, 2 H, piperidine H), 4.02 (s, 3 H, OCH3), 4.13 (br. s, 2 H, 
piperidine H), 5.86 (br. s, 1 H, piperidine H), 6.90 (d, J = 8.5 Hz, 1 H, 3-H), 7.32 (t, J = 
7.6 Hz, 1 H, aromatic H), 7.48 (dd, J = 1.5, 7.3 Hz, 1 H, aromatic H), 7.63 (dd, J = 1.2, 
7.8 Hz, 1 H, aromatic H), 7.97 (d, J = 8.8 Hz, 1 H, aromatic H). − 13C NMR (125.7 
MHz, CDCl3): δ = 24.54 (Cpiper), 28.51 (OC(CH3)3), 29.84, 42.32 (all Cpiper), 53.37 
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(OCH3), 79.52 (OC(CH3)3), 112.71, 123.80, 125.13, 126.99, 128.81, 139.06, 139.74, 
144.03, 161.37 (all Carom). – C20H24N2O3 (340.42): calcd. C 70.56, H 7.11, N 8.23, found 
C 70.50, H 7.16, N 8.17. 
 
3.2.20. Synthesis of tert-Butyl 4-(2-methoxyquinolin-8-yl) piperidine-1-
carboxylate (38) 
To a solution of compound 37 (0.6 g, 1.76 mmol) in a mixture of THF (5 mL) and 
EtOH (10 mL) was added Pd-C (10% wet basis, 0.4 g) and the mixture was subjected to 
hydrogenation in Parr apparatus at 60 psi for 7 hours. After filtering over the pad of 
celite, the solution was concentrated and chromatographed on silica column, eluting with 
ethyl acetate:hexanes (20:80) to get the title compound as off-white solid (0.57 g, yield 
94 %). M.p. 72-73 oC. – IR (neat): ν = 3031, 2935, 1675, 1608, 1484 cm-1. − 1H NMR 
(500 MHz, CDCl3): δ = 1.42 (s, 9 H, OC(CH3)3), 1.71 (m, 2 H, piperidine H), 1.95 (m, 2 
H, piperidine H), 2.88 (m, 2 H, piperidine H), 3.82 (m, 1 H, piperidine H), 3.99 (s, 3 H, 
OCH3), 4.22 (br. s, 2 H, piperidine H), 6.84 (d, J = 8.5 Hz, 1 H, 3-H), 7.28 (m, 1 H, 
aromatic H), 7.38 (m, 1 H, aromatic H), 7.51 (m, 1 H, aromatic H), 7.97 (d, J = 8.8 Hz, 1 
H, aromatic H). − 13C NMR (125.7 MHz, CDCl3): δ = 28.48 (OC(CH3)3), 32.15, 36.84, 
42.84 (all Cpiper), 53.23 (OCH3), 79.30 (OC(CH3)3), 112.38, 123.89, 124.96, 125.64, 
126.04, 139.40, 143.93 (all Carom), 155.21 (C=O), 161.67 (Carom). – C20H26N2O3 
(342.43): calcd. C 70.15, H 7.65, N 8.18; found C 70.10, H 7.70, N, 8.11. 
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3.2.21. Synthesis of ynt2-Methoxy-8-(piperidin-4-yl) quinoline (10) 
 The title compound 10 was obtained from compound 37 as an off-white solid 
(0.46 g, yield 92 %).  M.p. 142-144 oC. – IR (neat): ν = 3031, 2982, 1612, 1441, 1213 
cm-1. − 1H NMR (500 MHz, [D6]DMSO): δ = 1.99 (m, 2 H, piperidine H), 2.14 (m, 2 H, 
piperidine H), 3.16 (m, 2 H, piperidine H), 3.45 (m, 2 H, piperidine H), 4.01 (s, 3 H, 
OCH3), 7.01 (d, J = 8.2 Hz, 1 H, 3-H), 7.41 (m, 1 H, aromatic H), 7.51 (m, 1 H, aromatic 
H), 7.92 (d, J = 8.3 Hz, 1 H, aromatic H). 13C NMR (125.7 MHz, [D6]DMSO): δ = 
28.72, 31.00, 34.40, 36.02, 44.33 (all Cpiper), 53.28 (OCH3), 112.76, 114.52, 116.83, 
124.23, 126.19, 126.48, 140.10, 158.76, 161.23 (all Carom). – C17H19F3N2O3 (356.34): 
calcd. C 57.30, H 5.37, N 7.86; found C 57.24, H 5.42, N 7.80. 
3.2.22. Synthesis of 2-(benzyloxy)-8-bromoquinoline (39) 
 To a solution of benzyl alcohol (3.57 g, 33.0 mmol) in DMF (30 mL) at 0 oC was 
added NaH (0.95 g, 39.6 mmol) and after being stirred for 10 minutes at room 
temperature, compound 22 (4 g, 16.53 mmol) was added and the mixture was stirred at 
60 oC for 5 h. The reaction was diluted with ethyl acetate (100 mL) and washed with 
H2O (20 mL), brine (3 x 20 mL), dried over Na2SO4 and evaporated. Column 
chromatography on silica column eluting with hexanes:ethyl acetate (1:1) yielded 
compound 39 as a white crystalline solid (4.67 g, 90%).1H-NMR (500 MHz, CDCl3) δ: 
5.63 (s, 2H), 6.96 (d, 1H), 7.24 (m, 1H), 7.32 (m, 1H), 7.37-7.40 (m, 2H), 7.62 (m, 2H), 
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7.67 (dd, 2H), 7.93-7.97 (m, 2H). 13C NMR (125.7 MHz, CDCl3) δ: 68.0, 114.05, 
122.56, 124.47, 126.29, 127.10, 128.01, 128.41, 128.89, 133.10, 137.10, 139.29, 143.63, 
162.25. 
 
3.2.23. Synthesis of compound 1-Benzyl-4-(2-(benzyloxy) quinolin-8-yl) 
piperidin-4-ol (40) 
A solution of 2-(benzyloxy)-8-bromoquinoline 39(2.0 g, 6.4 mmol) in THF (20 
mL) was added dropwise over 10 min to a solution of n-BuLi (2.5 M, 2.8 mL, 7 mmol) 
in hexane cooled to -78 °C. The mixture was stirred for 1 h at -78 °C, and a solution of 
1-benzylpiperidone 39 (1.21 g, 6.4 mmol) in THF (10 mL) was added dropwise over a 
period of 10 min, maintaining the reaction temperature at -78 °C. The resulting mixture 
was stirred at -78 °C for 0.5 h and at -10 °C for 1.5 h whereupon a saturated solution of 
ammonium chloride (4 mL) was added. The reaction mixture was stirred and warmed to 
room temperature. Water (50 mL) was added to the reaction mixture and extracted with 
dichloromethane (3 x 30 mL). The combined organic extracts were washed with water, 
dried with Na2SO4, and filtered. The solvent was removed under reduced pressure and 
the crude product was purified by flash chromatography (1M NH3 in 
MeOH/dichloromethane, 2:98 to 7:93) to afford the title compound 40 as dark brown 
thick oil (1.84 g 68 %). – IR (neat): ν = 3365, 3042, 3032, 2971, 1607, 1485, 1260, 1192 
cm-1. − 1H NMR (500 MHz, CDCl3): δ = 2.15 (br. s, 4 H, piperidine H), 2.73-2.78 (m, 5 
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H, piperidine H, OH), 3.62 (s, 2 H, NCH2), 5.43 (s, 2 H, OCH2), 6.99 (d, J = 9.0 Hz, 1 
H, 3-H), 7.23-7.47 (m, 11 H, aromatic H), 7.60 (m, 2 H, aromatic H), 8.04 (d, J = 8.5 
Hz, 1 H, 4-H). − 13C NMR (125.7 MHz, CDCl3): δ = 37.26, 49.46 (all Cpiper), 53.02 
(OCH2), 63.52 (NCH2), 68.48 (Cpiper), 113.21 (C-3), 124.75, 126.30, 127.48, 127.80, 
128.05, 128.54, 128.70, 128.87, 129.08, 129.39, 129.93, 136.84, 141.18, 142.25, 144.64 
(all Carom), 160.31 (C-2). – C42H44N4O3 (652.82): calcd. C 77.27, H 6.79, N 8.58; found 
C 77.20, H 6.84, N 8.51. 
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3.2.24. Synthesis of compound 8-(1-Benzyl-1, 2, 3, 6-tetrahydropyridin-
4-yl) quinolin-2(1H)-one (41) 
A solution of compound 40 (1.5 g, 5.35 mmol) in a mixture of methanol (15 mL) 
and concentrated HCl (15 mL) was heated at reflux temperature for 5 h. The reaction 
mixture was cooled and the solvent was removed under reduced pressure to give crude 
product as a hydrochloride salt, which was converted to the free base (aq NaOH/ethyl 
acetate) and purified by column chromatography eluting with ethyl acetate/hexane 
(20:80 to 40:60) to afford the title compound 41 as a light yellow gum (0.95 g, 56 %). – 
IR (neat): ν = 3182, 3054, 3022, 2978, 1638, 1610, 1465 cm-1.− 1H NMR (500 MHz, 
CDCl3): δ = 2.15 (br. s, 2 H, piperidine H), 2.97 (t, J = 5.5 Hz, 2 H, piperidine H), 3.34 
(br. s, 2 H, piperidine H), 3.87 (s, 2 H, NCH2Ph), 5.79 (br. s, 1 H, piperidine H), 6.62 (d, 
J = 9.5 Hz, 1 H, 3-H), 7.18 (t, J = 7.5 Hz, 1 H, aromatic H), 7.28-7.47 (m, 8 H, aromatic 
H), 7.76 (d, J = 9.5 Hz, 1 H, 4-H), 10.17 (br. s, 1 H, NHCO). − 13C NMR (125.7 MHz, 
CDCl3): δ = 31.52, 48.1, 51.9, 115.82 (all Cpiper), 120.93, 123.73, 124.66, 127.58, 
128.07, 128.66, 128.88, 129.49, 129.99, 134.85, 136.44, 141.10, 141.85 (all Carom), 
160.32 (C-2). – C21H20N2O (316.40): calcd. C 79.72, H 6.37, N 8.85; found C 79.66, H 
6.41, N 8.80. 
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3.2.25. Synthesis of compound tert-Butyl 4-(2-(benzyloxy) quinolin-8-
yl)-5,6-dihydropyridine-1(2H)-carboxylate (42) 
 Nitrogen was flushed for 3 minutes in a flask containing a solution of the 
boronate 30 (1.39 g, 4.5 mmol), K2CO3 (1.86 g, 13.5 mmol) and bromide 10 (1.49 g, 
4.74 mmol) in DMF (30 mL), followed by the addition of PdCl2dppf (0.23 g, 0.28 
mmol). The reaction mixture was heated to 80 °C and stirred under N2 overnight, cool to 
room temperature and filtered through a pad of celite. The filtrate was added ethyl 
acetate (50 mL) and washed successively with water (20 mL), brine (3 x 15 mL), dried 
over Na2SO4 and evaporated. Column chromatography of the brown oily material on 
silica gel, eluting with ethyl acetate:hexanes (10:90) and then changing to (25:75) gave 
the title compound 41 as light yellow amorphous solid (0.97 g, 52 %). – IR (neat): ν = 
3043, 3021, 2978, 1681, 1607, 1442, 1175 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.49 
(s, 9 H, OC(CH3)3), 2.76 (br. s, 2 H, piperidine H), 3.68 (br. s, 2 H, piperidine H), 4.13 
(br. s, 2 H, piperidine H), 5.49 (s, 2 H, OCH2Ph), 5.85 (br. s, 1 H, piperidine H), 6.95 (d, 
J = 8.8 Hz, 1 H, aromatic H), 7.30-7.38 (m, 4 H, aromatic H), 7.46-7.48 (m, 3 H, 
aromatic H), 7.63 (dd, J = 1.5, 7.9 Hz, 1 H, aromatic H), 7.99 (d, J = 8.8 Hz, 1 H, 
aromatic H). − 13C NMR (125.7 MHz, CDCl3): δ = 28.77 (OC(CH3)3), 30.18, 44.32, 
67.73 (all Cpiper), 79.74 (OC(CH3)3), 113.18, 124.14, 125.55, 127.22, 128.04, 128.20, 
128.66, 129.12, 137.51, 139.51, 140.12, 144.24 (all Carom), 155.60 (C=O), 161.02 
(Carom). – C26H28N2O3 (416.51): calcd. C 74.97, H 6.78, N 6.73; found C 74.91, H 6.83, 
N 6.67. 
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3.2.26. Synthesis of tert-Butyl 4-(2-oxo-1, 2, 3, 4-tetrahydroquinolin-8-
yl) piperidine-1-carboxylate (43) 
 To a solution of compound 42 (0.7 g, 1.68 mmol) in a mixture of THF (5 mL) 
and EtOH (10 mL) was added Pd-C (10% wet basis, 0.5 g) and the mixture was 
subjected to hydrogenation in Parr apparatus at 50 psi for 6 hours. After being filtered 
through a pad of celite, the solution was concentrated to get brown oily material, which 
was resolved over silica column eluting with ethyl acetate:hexanes (30:70) and then 
changing to (60:40) to get compound 43 as an off-white solid (0.15 g, 27 %). M.p. 132-
134 oC. – IR (neat): ν = 3245, 3019, 2971, 1668, 1603, 1472 cm-1. − 1H NMR (500 MHz, 
CDCl3): δ = 1.49 (s, 9 H, OC(CH3)3), 1.61 (m, 2 H, piperidine H), 1.69 (m, 2 H, 
piperidine H), 2.61 (m, 2 H, 4-H), 2.79 (m, 1 H, piperidine H), 2.85 (br. s, 2 H, 
piperidine H), 2.93 (m, 2 H, 3-H), 4.28 (br. s, 2 H, piperidine H), 6.97 (t, J = 7.6 Hz, 1 
H, aromatic H), 7.04-7.09 (m, 2 H, aromatic H), 8.30 (br. s, 1 H, NHCO). − 13C NMR 
(125.7 MHz, CDCl3): δ = 26.00 (C-4), 28.45 (OC(CH3)3), 30.68 (C-3), 32.13, 35.62 (all 
Cpiper), 79.56 (OC(CH3)3), 123.18, 124.48, 124.75, 126.02, 130.65, 134.23 (all Carom), 
154.75 (C=O), 172.03 (C-2). – C19H26N2O3 (330.42): calcd. C 69.06, H 7.93, N 8.48; 
found C 69.00, H 7.98, N 8.41. 
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3.2.27. Synthesis of tert-Butyl 4-(2-oxo-1, 2-dihydroquinolin-yl) 
piperidine-1-carboxylate(44) 
The title compound 44 was obtained from the reaction described for compound 43 
as a light yellow solid (0.36 g, yield 65 %). M.p. 101-103 oC. – IR (neat): ν = 3172, 
3031, 2965, 1645, 1603, 1461, 1112 cm-1.− 1H NMR (500 MHz, CDCl3): δ = 1.50 (s, 9 
H, OC(CH3)3), 1.69 (m, 2 H, piperidine H), 1.91 (m, 2 H, piperidine H), 3.10 (br. s, 2 H, 
piperidine H), 3.42 (m, 1 H, piperidine H), 4.30 (br. s, 2 H, piperidine H), 6.67 (d, J = 
9.5 Hz, 1 H, 3-H), 7.20 (t, J = 7.6 Hz, 1 H, aromatic H), 7.40-7.45 (m, 2 H, aromatic H), 
7.78 (t, J = 7.6 Hz, 1 H, 4-H). − 13C NMR (125.7 MHz, CDCl3): δ = 28.48 (OC(CH3)3), 
30.29, 32.33, 34.70 (all Cpiper), 79.49 (OC(CH3)3), 120.20, 121.24, 122.54, 123.84, 
126.41, 127.76, 131.38, 135.78, 141.74 (all Carom), 154.83 (C=O), 163.99 (Carom), 172.58 
(C=O). – C19H24N2O3 (328.41): calcd. C 69.49, H 7.37, N 8.53; found C 69.45, H 7.43, 
N 8.46. 
3.2.28. Synthesis of 8-(Piperidin-4-yl) quinolin-2(1H)-one (11) 
 To a solution of 44 (0.5 g, 1.52 mmol) in CH2Cl2 (15 mL) was added 
trifluoroacetic acid (3 mL) at 0 oC and the reaction mixture was stirred for 6 h at room 
temperature. Solvents were evaporated under reduced pressure and triturating with 
diethyl ether gave the title compound 11 as trifluoroacetic acid salt as an off-white solid 
(0.45 g, 90 %).  M.p. 256-258 oC. – IR (neat): ν = 3266, 3031, 3011, 2990, 1672, 1618, 
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1445 cm-1.− 1H NMR (500 MHz, [D6]DMSO): δ = 1.86 (br. s, 4 H, piperidine H), 3.08 
(m, 2 H, piperidine H), 3.42 (m, 2 H, piperidine H), 3.48 (m, 1 H, piperidine H), 6.51 (d, 
J = 9.4 Hz, 1 H, 3-H), 7.19 (t, J = 8.1 Hz, 1 H, aromatic H), 7.37 (d, J = 8.0 Hz, 1 H, 
aromatic H), 7.54 (d, J = 7.9 Hz, 1 H, aromatic H H), 7.91 (d, J = 9.5 Hz, 1 H, 4-H), 
8.49 (br. s, 1 H, NHCO).− 13C NMR (125.7 MHz, [D6]DMSO): δ = 28.91, 31.68, 44.05 
(all Cpiper), 119.91, 121.60, 122.31, 127.09, 127.56, 129.40, 136.09, 141.55 (all Carom), 
162.92 (C=O).– C16H17F3N2O3 (342.31): calcd. C 56.14, H 5.01, N 8.18; found C 56.08, 
H 5.06, N 8.11. 
3.2.29. Synthesis of 8-(Piperidin-4-yl)-3, 4-dihydroquinolin-2(1H)-one 
(12) 
 Following the same procedure adopted for the synthesis of 11, the title 
compound was obtained from compound 43 as off-white solid (0.70 g, yield 89 %). M.p. 
247-248 oC. – IR (neat): ν = 3221, 3021, 2988, 1660, 1603, 1445, 1186 cm-1.− 1H NMR 
(500 MHz, [D6]DMSO): δ = 1.79 (m, 4 H, piperidine H), 2.51 (m, 2 H, 2-H), 2.85 (m, 2 
H, 3-H), 2.99-3.06 (m, 3 H, piperidine H), 3.34 (m, 2 H, piperidine H), 6.96 (m, 1 H, 
aromatic H), 7.07 (m, 1 H, aromatic H), 9.63 (s, 1 H, NHCO). − 13C NMR (125.7 MHz, 
[D6]DMSO): δ = 25.88 (C-4), 29.22 (Cpiper), 30.88 (C-3), 32.29, 44.82 (all Cpiper), 
123.05, 124.68, 125.63, 126.62, 130.45, 135.37 (all Carom), 170.02 (C=O).– 
C16H19F3N2O3 (344.33): calcd. C 55.81, H 5.56, N 8.14; found C 55.74, H 5.62, N 8.08. 
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3.2.30. Synthesis of 8-(1-(Biphenyl-4-ylmethyl) piperidin-4-yl)-2-
methoxyquinoline (10a) 
To a solution of compound 10 (0.15 g, 0.42 mmol) and biphenyl-4-carbaldehydea 
(0.1 g, 0.55 mmol) in 1,2-dichloroethane (5 mL) at 0 oC was added Et3N (0.13 mL, 0.97 
mmol). After being stirred for 10 min at room temperature, NaBH(OAc)3(0.11 g, 0.53 
mmol) was added and reaction mixture was stirred for 6 h. The reaction was added sat. 
NaHCO3 solution (10 mL) and stirred for 15 min, followed by the addition of ethyl 
acetate (30 mL). The organic layer was separated and washed with sat. NaHCO3, brine, 
and dried over Na2SO4. Purification of the brown oily material on silica column, eluting 
with ethyl acetate:hexanes (70:30) and then changing to ethyl acetate (100%) yielded the 
titled compound 10a as a light yellow solid 0.126 g, yield 45 %). M.p. 84-85 oC. – IR 
(neat): ν = 3031, 3021, 2936, 1609, 1444, 1186, 1120 cm-1. − 1H NMR (500 MHz, 
CDCl3): δ = 2.15 (m, 2 H, piperidine H), 2.36 (m, 2 H, piperidine H), 2.85 (br. s, 2 H, 
piperidine H), 3.64 (m, 2 H, piperidine H), 4.03 (s, 3 H, OCH3), 4.20 (s, 2 H, NCH2), 
6.88 (d, J = 8.8 Hz, 1 H, 3-H), 7.32-7.38 (m, 2 H, aromatic H), 7.45 (t, J = 7.3 Hz, 2 H, 
aromatic H), 7.51 (d, J = 7.3 Hz, 1 H, aromatic H), 7.56-7.59 (m, 4 H, aromatic H), 7.63 
(m, 2 H, aromatic H), 7.95 (d, J = 8.5 Hz, 1 H, aromatic H). − 13C NMR (125.7 MHz, 
CDCl3): δ = 29.47, 34.92 (all Cpiper), 53.14 (OCH3), 61.71 (NCH2), 112.62 (C-3), 
123.98, 124.98, 126.21, 127.06, 127.72, 128.85, 131.30, 139.31, 139.55, 140.02, 142.37, 
143.86 (all Carom), 161.44 (C-2). – C28H28N2O (408.53): calcd. C 82.32, H 6.91, N 6.86; 
found C 82.25, H 6.96, N 6.79. 
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3.2.31. Synthesis of 8-(4-((4'-Fluorobiphenyl-4-yl) methyl) piperazin-1-
yl)-2-methoxyquinoline (10b) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 10 and b as an off-white solid (yield 
37 %). M.p. 94-95 oC. – IR (neat): ν = 3042, 3011, 2926, 1603, 1440, 1183, 1132 cm-1. − 
1H NMR (500 MHz, CDCl3): δ = 1.92 (m, 2 H, piperidine H), 2.02 (m, 2 H, piperidine 
H), 2.30 (m, 2 H, piperidine H), 3.18 (m, 2 H, piperidine e H), 3.70 (s, 2 H, NCH2), 3.83 
(m, 1 H, piperidine H), 4.05 (s, 3 H, OCH3), 6.88 (d, J = 8.5 Hz, 1 H, 3-H), 7.09-7.12 
(m, 2 H, aromatic H), 7.32 (t, J = 7.6 Hz, 1 H, aromatic H), 7.45-7.56 (m, 8 H, aromatic 
H), 7.94 (d, J = 8.8 Hz, 1 H, aromatic H). − 13C NMR (125.7 MHz, CDCl3): δ = 32.03, 
36.07 (all Cpiper), 53.07 (OCH3), 54.66 (Cpiper), 62.95 (NCH2), 112.36 (C-3), 115.49, 
115.66, 123.85, 124.91, 125.41, 125.81, 126.84, 128.52, 128.57, 129.97, 136.71, 136.98, 
139.17, 142.32, 144.13 (all Carom), 161.20 (C-2). – C28H27FN2O (426.53): calcd. C 
78.85, H 6.38, N 6.57; found C 78.79, H 6.44, N, 6.50. 
3.2.32. Synthesis of 2-Methoxy-8-(4-((5-phenylpyridin-3-yl)methyl) 
piperazin-1-yl)quinoline (10c) 
 Following the same procedure adopted for the synthesis of 10a, the title 
compound was obtained by reductive amination of compound 10 and c as an off white 
solid (yield 35 %). M.p. 135-137 oC. – IR (neat): ν = 3021, 2945, 1601, 1433, 1263, 
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1228 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.90 (m, 2 H, piperidine H), 2.02 (m, 2 H, 
piperidine H), 2.30 (m, 2 H, piperidine H), 3.09 (m, 2 H, piperidine H), 3.67 (s, 2 H, 
NCH2), 3.82 (m, 1 H, piperidine H), 4.07 (s, 3 H, OCH3), 6.88 (d, J = 8.8 Hz, 1 H, 3-H), 
7.33 (t, J = 7.6 Hz, 1 H, aromatic H), 7.41 (d, J = 7.3 Hz, 1 H, aromatic H), 7.47-7.53 
(m, 3 H, aromatic H), 7.64 (m, 2 H, aromatic H), 7.94 (m, 2 H, aromatic H), 8.59 (d, J = 
1.8 Hz, 1 H, aromatic H), 8.77 (d, J = 2.1 Hz, 1 H, aromatic H). − 13C NMR (125.7 
MHz, CDCl3): δ = 32.33, 36.36 (all Cpiper), 53.05 (OCH3), 54.79 (Cpiper), 60.65 (NCH2), 
112.32 (C-3), 124.88, 125.33, 125.77, 127.16, 127.98, 128.97, 134.08, 135.05, 136.23, 
137.81, 139.11, 142.49, 144.13, 146.95, 149.17 (all Carom), 161.13 (C-2). − C27H27N3O 
(409.52): calcd. C 79.19, H 6.65, N 10.26; found C 79.12, H 6.71, N 10.19. 
3.2.33. Synthesis of 8-(4-((5-(4-Fluorophenyl) pyridin-3-yl) methyl) 
piperazin-1-yl)-2-methoxyquinoline (10d) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 10 and d as a light brown solid (yield 
32 %). M.p. 156-158 oC. – IR (neat): ν = 3025, 2931, 1607, 1431, 1266 cm-1. − 1H NMR 
(500 MHz, CDCl3): δ = 1.89 (m, 2 H, piperidine H), 2.01 (m, 2 H, piperidine H), 2.28 
(m, 2 H, piperidine H), 3.05 (m, 2 H, piperidine H), 3.65 (s, 2 H, NCH2), 3.81 (m, 1 H, 
piperidine H), 4.06 (s, 3 H, OCH3), 6.88 (d, J = 8.5 Hz, 1 H, 3-H), 7.16 (m, 2 H, 
aromatic H), 7.33 (t, J = 7.6, 1 H, aromatic H), 7.51 (dd, J = 1.2, 7.3 Hz, 1 H, aromatic 
H), 7.54-7.59 (m, 3 H, aromatic H), 7.89 (m, 1 H, aromatic H), 7.94 (d, J = 8.8 Hz , 1 H, 
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aromatic H), 8.59 (d, J = 1.5 Hz, 1 H, aromatic H), 8.77 (d, J = 2.1 Hz, 1 H, aromatic H). 
− 13C NMR (125.7 MHz, CDCl3): δ = 32.33, 36.35 (all Cpiper), 53.04 (OCH3), 54.82 
(Cpiper), 60.62 (NCH2), 112.34 (C-3), 115.86, 116.03, 123.78, 124.90, 125.36, 125.77, 
128.80, 128.85, 133.92, 134.22, 134.89, 135.33, 139.12, 142.47, 144.13, 146.76, 149.17, 
161.13, 163.82 (all Carom). − C27H26FN3O (427.51): calcd. C 75.85, H 6.13, N 9.83; 
found C 75.79, H 6.19, N 9.76. 
3.2.34. Synthesis of 8-(4-(3-Cyclopentenylbenzyl) piperazin-1-yl)-2-
methoxyquinoline (10e) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound10 and e as a light yellow solid (yield 
46 %). M.p. 125-126 oC. – IR (neat): ν = 3028, 2982, 2898, 1605, 1472, 1445, 1263, 
1258 cm-1.− 1H NMR (500 MHz, CDCl3): δ = 1.85-192 (m, 2 H, piperidine H), 1.98-
2.04 (m, 4 H, piperidine H, cyclopent H), 2.24 (m, 2 H, cyclopent H), 2.72 (m, 2 H, 
cyclopent H), 3.05 (m, 2 H, piperidine H), 3.60 (s, 2 H, NCH2), 3.79 (m, 1 H, piperidine 
H), 4.05 (s, 3H, OCH3), 6.20 (s, 1 H, cyclopent H), 6.85 (d, J = 8.8 Hz, 1 H, 3-H), 7.24-
7.34 (m, 4 H, aromatic H), 7.45-7.54 (m, 3 H, aromatic H), 7.91 (d, J = 8.8 Hz, 1 H, 
aromatic H). − 13C NMR (125.7 MHz, CDCl3): δ = 23.33 (Ccyclopent), 32.33 (Cpiper), 
33.22, 33.30 (all Ccyclopent), 36.32 (Cpiper), 53.05 (OCH3), 54.74 (Cpiper), 63.62 (NCH2), 
112.34 (Ccyclopent), 123.80, 124.27, 124.87, 125.28, 125.80, 126.12, 126.46, 127.88, 
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128.10, 136.67, 138.29, 139.11, 142.41, 142.67, 144.13, 161.12 (all Carom). − C27H30N2O 
(398.54): calcd. C 81.37, H 7.59, N 7.03; found C 81.31, H 7.64, N 6.97. 
3.2.35. Synthesis of S8-(4-((5-Cyclopentenylpyridin-3-yl) methyl) 
piperazin-1-yl)-2-methoxyquinoline (10f) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 10and f as a light yellow amorphous 
solid (yield 39 %). M.p. 85-86 oC. – IR (neat): ν = 3021, 2992, 2828, 1601, 1472, 1445, 
1255 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.89-194 (m, 2 H, piperidine H), 2.02-
2.09 (m, 4 H, piperidine H, cyclopent H), 2.26-2.31 (m, 2 H, cyclopent H), 2.73 (m, 2 H, 
cyclopent H), 3.09 (m, 2 H, piperidine H), 3.61 (s, 2 H, NCH2), 3.80 (m, 1 H, piperidine 
H), 4.05 (s, 3 H, OCH3), 6.30 (s, 1 H, cyclopent H), 6.87 (d, J = 8.5 Hz, 1 H, 3-H), 7.32 
(m, 1 H, aromatic H), 7.49 (d, J = 7.3 Hz, 1 H, aromatic H), 7.55 (d, J = 7.9 Hz, 1 H, 
aromatic H), 7.76 (s, 1 H, aromatic H), 7.95 (d, J = 8.8 Hz, 1 H, aromatic H), 8.42 (s, 1 
H, aromatic H), 8.59 (s, 1 H, aromatic H). − 13C NMR (125.7 MHz, CDCl3): δ = 23.16 
(Ccyclopent), 32.09 (Cpiper), 32.88, 33.36 (all Ccyclopent), 36.24 (Cpiper), 53.03 (OCH3), 54.57 
(Cpiper), 60.46 (NCH2), 112.32 (Ccyclopent), 123.77, 124.87, 125.36, 125.78, 128.35, 
132.04, 133.14, 133.59, 139.10, 139.38, 142.34, 144.10, 145.74, 148.46 (all Carom), 
161.14 (C-2). − C26H29N3O (399.53): calcd. C 78.16, H 7.32, N 10.52; found C 78.10, H 
7.38, N 10.45. 
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3.2.36. Synthesis of 8-(4-(Biphenyl-4-ylmethyl) piperazin-1-yl) quinolin-
2(1H)-one (11a) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 11 and a as a light yellow solid (yield 
45 %). M.p. 146-148 oC. – IR (neat): ν = 3193, 3038, 3021, 2938, 1641, 1601, 1437, 
1218 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.81 (m, 4 H, piperidine H), 2.26 (m, 2 H, 
piperidine H), 3.00 (br. s, 3 H, piperidine H), 3.60 (s, 2 H, NCH2), 6.65 (d, J = 9.4 Hz, 1 
H, 3-H), 7.10 (t, J = 8.7 Hz, 1 H, aromatic H), 7.34-7.55 (m, 5 H, aromatic H), 7.61 (d, J 
= 9.4 Hz, 1 H, 4-H), 10.12 (br. s, 1 H, NHCO).− 13C NMR (125.7 MHz, CDCl3): δ = 
32.41, 34.93, 53.83 (all Cpiper), 63.03 (NCH2), 119.99, 121.17, 122.47, 126.18, 126.92, 
127.03, 127.16, 127.78, 128.73, 129.75, 131.41, 135.71, 137.02, 139.95, 140.92, 141.61 
(all Carom), 163.46 (C=O). – C27H26N2O (394.51): calcd. C 82.20, H 6.64, N 7.10; found 
C 82.14, H 6.70, N 7.03. 
3.2.37. Synthesis of 8-(4-((4'-Fluorobiphenyl-4-yl) methyl) piperazin-1-
yl) quinolin-2(1H)-one (11b) 
 Following the same procedure adopted for the synthesis of 10a, the title 
compound was obtained by reductive amination of compound 11 and b as an off white 
solid (yield 41 %). M.p. 159-161 oC. – IR (neat): ν = 3213, 3028, 2928, 1637, 1609, 
1447, 1171 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.88 (m, 4 H, piperidine H), 2.24 
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(m, 2 H, piperidine H), 2.90 (m, 1 H, piperidine H), 3.08 (m, 2 H, piperidine H), 3.65 (s, 
2 H, NCH2), 6.62 (d, J = 9.4 Hz, 1 H, 3-H), 7.12 (t, J = 8.7 Hz, 1 H, aromatic H), 7.20 (t, 
J = 8.5 Hz, 1 H, aromatic H), 7.41-7.44 (m, 4 H, aromatic H), 7.52-7.58 (m, 5 H, 
aromatic H), 7.73 (d, J = 9.4 Hz, 1 H, 4-H), 9.55 (br. s, 1 H, NHCO).− 13C NMR (125.7 
MHz, CDCl3): δ = 32.32, 35.36, 54.03 (all Cpiper), 63.02 (NCH2), 115.52, 115.73, 
120.06, 121.21, 122.62, 126.32, 126.86, 127.82, 128.56, 128.64, 129.77, 130.08, 135.66, 
137.05, 137.07, 139.03, 141.70 (all Carom), 161.32 (C=O), 163.11 (Carom). – C27H25FN2O 
(412.50): calcd. C 78.62, H 6.11, N 6.79; found C 78.56, H 6.16, N 6.72. 
3.2.38. Synthesis of 8-(4-((5-Phenylpyridin-3-yl) methyl) piperazin-1-yl) 
quinolin-2(1H)-one (11c) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 11 and c as a light yellow solid (yield 
38 %). M.p. 158-160 oC. – IR (neat): ν = 3363, 3051, 3018, 2932, 1643, 1600, 1433, 
1208 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.90 (m, 4 H, piperidine H), 2.17 (m, 2 H, 
piperidine H), 3.07 (m, 3 H, piperidine H), 3.71 (s, 2 H, NCH2), 6.59 (d, J = 9.5 Hz, 1 H, 
3-H), 7.21 (t, J = 7.6 Hz, 1 H, aromatic H), 7.41-7.43 (m, 2 H, aromatic H), 7.47-7.51 
(m, 4 H, aromatic H), 7.64 (m, 2 H, aromatic H), 7.7 (d, J = 9.4 Hz, 1 H, 4-H) 7.92 (s, 1 
H, aromatic H), 8.57 (d, J = 1.8 Hz, 1 H, aromatic H), 8.78 (d, J = 1.6 Hz, 1 H, aromatic 
H), 10.52 (br. s, 1 H, NHCO).− 13C NMR (125.7 MHz, CDCl3): δ = 32.28, 34.67, 53.84 
(all Cpiper), 60.47 (NCH2), 120.03, 121.06, 122.55, 126.26, 127.19, 127.81, 128.07, 
 51 
 
 
129.02, 131.34, 133.55, 135.16, 135.69, 136.31, 137.71, 141.73, 147.06, 149.16 (all 
Carom), 163.65 (C=O). Anal. Calcd for C26H25N3O (395.50): C, 78.96; H, 6.37; N, 
10.62%. Found: C, 78.90; H, 6.43; N, 10.57%. 
3.2.39. Synthesis of 8-(4-((5-(4-Fluorophenyl) pyridin-3-yl) methyl) 
piperazin-1-yl)quinolin-2(1H)-one (11d) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 11 and d as a light yellow solid (yield 
34 %). M.p. 161-163 oC. – IR (neat): ν = 3373, 3058, 3040, 2928, 1640, 1602, 1430, 
1228 cm-1. − 1H NMR (500 MHz, CDCl3): δ = 1.91 (m, 4 H, piperidine H), 2.39 (m, 2 H, 
piperidine H), 3.09 (m, 3 H, piperidine H), 3.71 (s, 2 H, NCH2), 6.62 (d, J = 11.8 Hz, 1 
H, 3-H), 7.18-7.22 (m, 4 H, aromatic H), 7.44-7.48 (m, 2 H, aromatic H), 7.59-7.62 (m, 
2 H, aromatic H), 7.80 (d, J = 11.2 Hz, 1 H, 4-H), 7.91 (br. s, 1 H, NH), 8.59 (d, J = 1.8 
Hz, 1 H, aromatic H), 8.75 (d, J = 1.8 Hz, 1 H, aromatic H), 10.20 (br. s, 1 H, NHCO).− 
13C NMR (125.7 MHz, CDCl3): δ = 32.26, 34.89, 53.99 (all Cpiper), 60.46 (NCH2), 
115.97, 116.18, 120.07, 121.15, 123.63, 126.38, 127.85, 128.89, 131.10, 133.87, 135.03, 
135.48, 141.77, 147.01, 149.24, 163.50, 164.36 (all Carom). − C26H24FN3O (413.49): 
calcd. C 75.52, H 5.85, N 10.16; found C 75.46, H 5.91, N 10.09. 
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3.2.40. Synthesis of 8-(4-(3-Cyclopentenylbenzyl) piperazin-1-yl) 
quinolin-2(1H)-one (11e) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 11and e as a white solid (yield 42 %). 
M.p. 123-125 oC. – IR (neat): ν = 3164, 3110, 3022, 3011, 2936, 2886, 1639, 1599, 
1471, 1116 cm-1.− 1H NMR (500 MHz, CDCl3): δ = 1.83-191 (m, 6 H, piperidine H, 
cyclopent H), 2.21-2.29 (m, 2 H, cyclopent H), 2.51-2.59 (m, 2 H, piperidine H), 2.73 
(m, 2 H, cyclopent H), 2.83 (m, 1 H, piperidine H), 3.08 (m, 2 H, piperidine H), 3.60 (s, 
2 H, NCH2), 6.22 (s, 1 H, cyclopent H), 6.60 (d, J = 9.4 Hz, 1 H, 3-H), 7.11-7.28 (m, 2 
H, aromatic H), 7.29 (t, J = 7.8 Hz, 1 H, aromatic H), 7.33 (m, 1 H, aromatic H), 7.42 
(m, 2 H, aromatic H), 7.52 (m, 1 H, aromatic H), 7.75 (d, J = 9.4 Hz, 1 H, 4-H), 9.36 (br. 
s, 1 H, NHCO). − 13C NMR (125.7 MHz, CDCl3): δ  = 23.37 (Ccyclopent), 32.27 (Cpiper), 
33.28, 33.34 (all Ccyclopent), 35.47, 53.99 (all Cpiper), 63.44 (NCH2), 119.94, 121.21, 
122.58, 124.37, 126.26, 126.43, 127.81, 128.18, 130.84, 135.47, 136.77, 137.01, 141.64, 
142.42 (all Carom), 162.98 (C=O). − C26H28N2O (384.51): calcd. C 81.21, H 7.34, N 7.29; 
found C 81.15, H 7.40, N 7.22. 
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3.2.41. Synthesis of 8-(4-((5-Cyclopentenylpyridin-3-yl) methyl) 
piperazin-1-yl)quinolin-2(1H)-one (11f) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 11 and f as an off white solid (yield 
31 %). M.p. 133-135 oC. – IR (neat): ν = 3169, 3026, 2934, 1639, 1601, 1411, 1190, 
1127 cm-1.− 1H NMR (500 MHz, CDCl3): δ = 1.81-191 (m, 4 H, piperidine H), 1.98-
2.10 (m, 2 H, cyclopent H), 2.25-2.36 (m, 2 H, cyclopent H), 2.52-2.59 (m, 2 H, 
piperidine H), 2.72 (m, 2 H, cyclopent H), 3.00 (m, 3 H, piperidine H), 3.59 (s, 2 H, 
NCH2), 6.30 (s, 1 H, cyclopent H), 6.57 (d, J = 9.4 Hz, 1 H, 3-H), 7.18 (t, J = 8.8 Hz, 1 
H, aromatic H), 7.41 (m, 2 H, aromatic H), 7.68 (s, 1 H, aromatic H), 7.76 (d, J = 9.4 
Hz, 1 H, 4-H), 8.40 (s, 1 H, aromatic H), 8.59 (s, 1 H, aromatic H), 10.18 (br. s, 1 H, 
NHCO). − 13C NMR (125.7 MHz, CDCl3): δ = 23.33 (Ccyclopent), 32.33 (Cpiper), 33.22, 
33.30 (all Ccyclopent), 36.32 (Cpiper), 53.05 (OCH3), 54.74 (Cpiper), 63.62 (NCH2), 113.98 
(Ccyclopent), 120.14 (Ar-C), 122.26, 122.41, 124.11, 128.50, 132.05, 132.59, 133.36, 
133.58, 138.80, 139.29, 140.65, 145.98, 148.45 (all Carom), 162.28 (C-2). − C25H27N3O 
(385.50): calcd. C 77.89, H 7.06, N 10.90; found C 77.83, H 7.12, N 10.83. 
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3.2.42. Synthesis of 8-(4-(Biphenyl-4-ylmethyl) piperazin-1-yl)-3, 4-
dihydroquinolin-2(1H)-one (12a) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 12 and a as an off white solid (yield 
41 %). M.p. 116-118 oC. – IR (neat): ν = 3217, 3053, 2912, 2872, 1668, 1601, 1482, 
1211 cm-1. − 1H NMR (500 MHz, CDCl3): δ =1.76-184 (m, 4 H, piperidine H), 2.15 (m, 
4 H, piperidine H), 2.53 (m, 1 H, piperidine H), 2.59 (t, J = 7.6, 2 H, 4-H), 2.94 (t, J = 
6.7, 2 H, 3-H), 3.05 (m, 2 H, piperidine H), 3.60 (s, 2 H, NCH2), 6.97-7.03 (m, 2 H, 
aromatic H), 7.15 (m, 1 H, aromatic H), 7.34 (m, 1 H, aromatic H), 7.41-7.45 (m, 4 H, 
aromatic H), 7.55  (d, J = 7.3, 1 H, aromatic H), 7.60  (d, J = 7.3, 1 H, aromatic H), 7.87 
(br. s, 1 H, NHCO). − 13C NMR (125.7 MHz, CDCl3): δ = 25.95 (C-4), 30.62 (C-3), 
32.24, 35.82, 54.07 (all Cpiper), 63.00 (NCH2), 123.09, 124.21, 124.80, 125.69, 126.92, 
127.01, 127.12, 128.69, 129.62, 130.91, 134.20, 137.22, 139.95, 140.91 (all Carom), 
171.68 (C-2). − C27H28N2O (396.52): calcd. C 81.78, H 7.12, N 7.06; found C 81.72, H 
7.17, N 7.00. 
3.2.43. Synthesis of 8-(4-((4'-Fluorobiphenyl-4-yl) methyl) piperazin-1-
yl)-3, 4-dihydroquinolin-2(1H)-one (12b) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 12 and b as an light yellow solid 
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(yield 33 %). M.p. 132-134 oC. – IR (neat): ν = 3223, 3050, 2902, 2862, 1667, 1600, 
1489, 1231 cm-1. − 1H NMR (500 MHz, CDCl3): δ =1.67-173 (m, 4 H, piperidine H), 
2.07 (m, 2 H, piperidine H), 2.50 (m, 3 H, piperidine H, 4-H), 2.83 (t, J = 7.6, 2 H, 3-H), 
2.96 (m, 2 H, piperidine H), 3.51 (s, 2 H, NCH2), 6.88-6.94 ((m, 2 H, aromatic H), 7.01-
7.12 ((m, 3 H, aromatic H), 7.32 (d, J = 7.6 Hz, 2 H, aromatic H), 7.39-7.49 ((m, 4 H, 
aromatic H), 7.94 (br. s, 1 H, NHCO). − 13C NMR (125.7 MHz, CDCl3): δ = 26.02 (C-
4), 30.71 (C-3), 32.30, 35.78, 54.10 (all Cpiper), 63.02 (NCH2), 115.52, 115.73, 123.16, 
124.31, 124.87, 125.87, 126.84, 128.56, 129.78, 131.05, 134.31, 137.08, 137.24, 139.04, 
161.32, 163.62 (all Carom), 170.87 (C=O). − C27H27FN2O (414.51): calcd. C 78.23, H 
6.57, N 6.76; found C 78.26, H 6.62, N 6.69. 
3.2.44. Synthesis of 8-(4-((5-Phenylpyridin-3-yl) methyl) piperazin-1-
yl)-3,4-dihydroquinolin-2(1H)-one (12c) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 12 and c as a light yellow gum (yield 
34 %). – IR (neat): ν =3213, 3032, 2922, 1662, 1608, 1472, 1201 cm-1.− 1H NMR (500 
MHz, CDCl3): δ = 1.76-189 (m, 4 H, piperidine H), 2.27 (m, 2 H, piperidine H), 2.56-
2.66 (m, 3 H, piperidine H, 4-H), 2.93 (m, 2 H, 3-H), 3.05 (m, 2 H, piperidine H), 3.67 
(s, 2 H, NCH2), 6.97 (m, 2 H, aromatic H), 7.07 (m, 1 H, aromatic H), 7.43 (m, 1 H, 
aromatic H), 7.50 (t, J = 7.5 Hz, 2 H, aromatic H), 7.89 (s, 1 H, aromatic H), 8.41 (s, 1 
H, aromatic H), 8.54 (s, 1 H, NHCO), 8.72 (s, 1 H, aromatic H).− 13C NMR (125.7 
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MHz, CDCl3): δ =25.93 (C-4), 30.63 (C-3), 31.93, 35.26, 53.85 (all Cpiper), 60.13 (s, 2 H, 
NCH2), 115.99, 116.20, 123.34, 124.43, 124.91, 125.96, 128.87, 128.95, 130.99, 133.68, 
134.21, 135.43, 146.80, 148.93, 161.76, 164.22 (all Carom), 172.50 (C=O). − C26H27N3O 
(397.51): calcd. C 78.56, H 6.85, N 10.57; found C 78.50, H 6.91, N 10.50. 
3.2.45. Synthesis of 8-(4-((5-(4-Fluorophenyl) pyridin-3-yl) methyl) 
piperazin-1-yl)-3,4-dihydroquinolin-2(1H)-one (12d) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 12 and d as a light yellow solid (yield 
30 %). M.p. 136-138 oC. – IR (neat): ν =3198, 3051, 2931, 1660, 1608, 1468, 1186 cm-1. 
− 1H NMR (500 MHz, CDCl3): δ = 1.74-189 (m, 4 H, piperidine H), 2.31 (m, 2 H, 
piperidine H), 2.56 (m, 2 H, 4-H), 2.72 (m, 1 H, piperidine H), 2.89 (m, 2 H, 3-H), 3.07 
(m, 2 H, piperidine H), 3.70 (s, 2 H, NCH2), 6.93-7.06 (m, 2 H, aromatic H), 7.13 (d, J = 
8.2 Hz, 1 H, aromatic H), 7.35-7.55 (t, J = 9.0 Hz, 3 H, aromatic H), 7.62 (m, 2 H, 
aromatic H), 7.93 (s, 1 H, aromatic H), 8.54 (s, 1 H, aromatic H), 9.61 (br. s, 1 H, 
NHCO).− 13C NMR (125.7 MHz, CDCl3): δ = 25.95 (C-4), 30.68 (C-3), 31.95, 35.04, 
53.69 (all Cpiper), 60.07 (NCH2), 123.30, 124.46, 124.93, 125.90, 127.20, 128.23, 129.10, 
131.25, 133.00, 134.37, 135.69, 136.55, 137.51, 146.91, 148.90 (all Carom), 172.66 
(C=O). – C26H26FN3O (415.50): calcd. C 75.16, H 6.31, N 10.11; found C 75.10, H 6.37, 
N 10.03. 
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3.2.46. Synthesis of 8-(4-(3-Cyclopentenylbenzyl) piperazin-1-yl)-3, 4-
dihydroquinolin-2(1H)-one (12e) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 12 and e as a light green solid (yield 
45 %). M.p. 115-117 oC. – IR (neat): ν = 3191, 3067, 2922, 2842, 1665, 1603, 1431, 
1188 cm-1.− 1H NMR (500 MHz, CDCl3): δ = 1.71-189 (m, 4 H, piperidine H), 1.98-
2.08 (m, 2 H, cyclopent H), 2.11-2.18 (m, 2 H, cyclopent H), 2.48-2.56 (m, 5 H, 
piperidine H, 4-H), 2.74 (m, 2 H, cyclopent H), 2.95 (m, 2 H, 3-H), 3.03 (m, 2 H, 
piperidine H), 3.57 (s, 2 H, NCH2), 6.22 (br. s, 1 H, cyclopent H), 6.94-7.13 (m, 2 H, 
aromatic H), 7.16 (d, J = 7.7 Hz, 1 H, aromatic H), 7.23 (d, J = 7.6 Hz, 1 H, aromatic H), 
7.25-7.32 (m, 2 H, aromatic H), 7.41 (s, 1 H, aromatic H), 7.98 (br. s, 1 H, NHCO). − 
13C NMR (125.7 MHz, CDCl3): δ = 23.40 (Ccyclopent), 26.04 (C-4), 30.71 (C-3), 32.31 
(Cpiper), 33.29, 33.37 (all Ccyclopent), 35.83, 54.07 (all Cpiper), 63.49 (NCH2), 123.13 
(Ccyclopent), 124.28, 124.37, 124.88, 125.83, 126.27, 126.26, 127.88, 128.18, 131.11, 
134.30, 136.82, 137.04, 142.42 (all Carom), 171.82 (C=O). − C26H30N2O (386.53): calcd. 
C 80.79, H 7.82, N 7.25; found C 80.73, H 7.88, N 7.18. 
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3.2.47. Synthesis of 8-(4-((5-cyclopentenylpyridin-3-yl) methyl) 
piperazin-1-yl)-3, 4-dihydroquinolin-2(1H)-one (12f) 
Following the same procedure adopted for the synthesis of 10a, the title compound 
was obtained by reductive amination of compound 12 and f as a light yellow solid (yield 
39 %). M.p. 123-125 oC. – IR (neat): ν = 3195, 3057,  2932, 2832, 1667, 1600, 1437, 
1182 cm-1.− 1H NMR (500 MHz, CDCl3): δ = 1.73-188 (m, 4 H, piperidine H), 2.00-
2.11 (m, 2 H, cyclopent H), 2.12-2.16 (m, 2 H, cyclopent H), 2.51-2.66 (m, 4 H, 
piperidine H, 4-H), 2.69-2.76 (m, 2 H, cyclopent H), 2.92-3.06 (m, 4 H, piperidine H, 3-
H), 3.57 (s, 2 H, NCH2), 6.31 (br. s, 1 H, cyclopent H), 6.92-7.12 (m, 2 H, aromatic H), 
7.16 (d, J = 7.7 Hz, 1 H, aromatic H), 7.69 (s, 1 H, aromatic H), 8.12 (br. s, 1 H, 
NHCO), 8.41  (s, 1 H, aromatic H), 8.59 (s, 1 H, aromatic H). − 13C NMR (125.7 MHz, 
CDCl3): δ = 23.25 (Ccyclopent), 26.03 (C-4), 30.71 (C-3), 32.25 (Cpiper), 32.99, 33.44 (all 
Ccyclopent), 35.62, 54.04 (all Cpiper), 60.57 (NCH2), 123.13 (Ccyclopent), 124.34, 124.84, 
125.88, 128.35, 130.98, 132.02, 133.07, 133.31, 134.33, 139.49, 146.02, 148.68 (all 
Carom), 171.87 (C=O). − C25H29N3O (387.52): calcd. C 77.48, H 7.54, N 10.84; found C 
77.42, H 7.60, N 10.77. 
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